Webinar: Supporting clinical trials during COVID-19

A free webinar is being provided for the Australian clinical trials sector to discuss the impacts of COVID-19 (Coronavirus).

Sector experts across the clinical trials eco-system, including, industry, regulators, health departments, HRECS, and sites, will provide information, advice and a chance to discuss the impacts. The webinar is independently conducted by PRAXIS.

Australian biotech companies are at the forefront of the global response to COVID-19, which is continuing to rapidly spread cross the world. This world-class biomedical research is part of a global vaccine development pipeline and is testimony to the substantial contribution the Australian life sciences ecosystem delivers to the world.

Clinical trials are worth around $1 billion to the Australian economy annually, inlcuding around $650 million of foreign investment, with Australia attracting trials from around the world. They are a critical component in the development process of bringing new therapies, devices and diagnostics to patients.

To register for this webinar, please visit PRAXIS Australia.